AHIP Statement On Proposed Changes To Lower Drug Costs In Medicare Part D

posted by Kristine Grow

on November 27, 2018

WASHINGTON, D.C. – Matt Eyles, president and CEO of America’s Health Insurance Plans (AHIP), issued this statement following the release of a proposed rule from the Centers from Medicare and Medicaid Services (CMS) targeting the costs of prescription drugs in Medicare Part D:

“Drug prices are out of control and leave too many Americans, including Medicare beneficiaries, to choose between paying their bills and paying for their medications.  The problem is the price, driven by monopolies in a broken market that empower branded drug makers to raise prices on the same product year after year. With more price hikes already announced for 2019 – enough is enough.

“We commend the Administration for its continued focus on reducing drug prices and appreciate its commitment to strengthen negotiating leverage, including for drugs for which rebates have often been limited or unavailable. This will enable Part D coverage providers to work even harder to lower costs for the patients they serve, while preserving access to the medications these patients need. For example, we agree that prudent use of formulary tools is essential to ensure the most effective and reasonably priced medicines are delivered to patients without unnecessary costs.

“We look forward to closely reviewing the policy and operational elements of all the proposals, participating in the comment period, and advancing market-based solutions that deliver real competition, create more consumer choice, and ensure open and honest manufacturer pricing.”

" "